Once-daily pravastatin compared with dietary advice in patients with borderline and moderate primary hypercholesterolemia

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Current Therapeutic Research-clinical and Experimental

• Publication date

  1995-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0011-393X(95)85035-X
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Pravastatin vs Gemfibrozil in the Treatment of Primary Hypercholesterolaemia

  1994cited by this paper
• Effects of One Year of Treatment with Pravastatin, an HMG‐CoA Reductase Inhibitor, on Lipoprotein a

  1993cited by this paper
• Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

  1993cited by this paper
• Efficacy of pravastatin in the treatment of hypercholesterolemia in clinical practice

  1992cited by this paper
• Effects of pravastatin and cholestyramine on gonadal and adrenal steroid production in familial hypercholesterolaemia.

  1991cited by this paper
• Effects of long-term administration of HMG-CoA reductase inhibitors on cholesterol synthesis in lens.

  1991cited by this paper
• Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolemia. The Italian Multicenter Pravastatin Study I.

  1991cited by this paper
• Concentrations of Pravastatin and Lovastatin in Cerebrospinal Fluid in Healthy Subjects

  1991cited by this paper
• Effects of pravastatin, a new HMG-CoA reductase inhibitor, on vitamin D synthesis in man.

  1991cited by this paper
• Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study.

  1990cited by this paper
• Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing.

  1990cited by this paper
• Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.

  1989cited by this paper
• Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel.

  1988cited by this paper
• The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects.

  1987cited by this paper
• Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

  1986cited by this paper
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper
• The Oslo Diet‐Heart Study: Eleven‐Year Report

  1970cited by this paper

• Cost-effectiveness of dietary supplement ingredients versus generic statins for LDL reduction

  2024cites this paper
• Pravastatin for lowering lipids.

  2020cites this paper
• Comparative Tolerability and Harms of Individual Statins: A Study-Level Network Meta-Analysis of 246 955 Participants From 135 Randomized, Controlled Trials

  2013cites this paper
• Systematic review and meta‐analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present

  2007cites this paper
• A comparative study of policosanol versus pravastatin in patients with type II hypercholesterolemia

  1997cites this paper